- •Duration of asymptomatic hypoglycemia was monitored with CGM in type 2 diabetes.
- •Post treatment MAGE was associated with hypoglycemia duration change from baseline.
- •The association was independent of treatment allocation and post treatment HbA1c.
The aim of this study was to examine the association between glycemic excursions and duration of hypoglycemia after treatment intensification in patients with type 2 diabetes (T2D).
Patients with T2D on oral anti-diabetes drug (OAD) with glycated hemoglobin (HbA1c) of 7.0–11.0% were switched to metformin monotherapy (500 mg thrice daily) for 8 weeks, followed by randomization to either glibenclamide or acarbose as add-on treatment for 16 weeks. Glycemic excursions were assessed as mean amplitude of glycemic excursions (MAGE) with 72-h ambulatory continuous glucose monitoring (CGM) before randomization and at the end of study. Hypoglycemia was defined as sensor glucose level of less than 60 mg/dl in two or more consecutive readings from CGM.
A total of 50 patients (mean age 53.5 ± 8.2 years, male 48%, mean baseline HbA1c 8.4 ± 1.2%) were analyzed. Duration of hypoglycemia significantly increased after treatment with glibenclamide (from 5.5 ± 13.8 to 18.8 ± 35.8 min/day, p = 0.041), but not with acarbose (from 2.9 ± 10.9 to 14.7 ± 41.9 min/day, p = 0.114). Post treatment MAGE was positively associated with change from baseline in duration of hypoglycemia after treatment with either glibenclamide (β coefficient 0.345, p = 0.036) or acarbose (β coefficient 0.674, p = 0.046). The association remained significant after multivariate adjustment (p < 0.05 for all models).
Post treatment glycemic excursions are associated with changes in duration of hypoglycemia after treatment intensification with OAD in patients with T2D. Glycemic excursions should be an important treatment target for T2D to reduce the risk of hypoglycemia.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998; 352: 837-853
- 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008; 359: 1577-1589
- Standards of medical care in diabetes.Diabetes Care. 2015; 38: S33-S40
- Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada.Can J Diabetes. 2008; 32: S1-S201
- Global guideline for type 2 diabetes.Diabetes Res Clin Pract. 2014; 104: 1-52
- Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.J Am Med Assoc. 2006; 295: 1681-1687
- Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.Diabetes. 2008; 57: 1349-1354
- The pathobiology of diabetic complications: a unifying mechanism.Diabetes. 2005; 54: 1615-1625
- Oxidative stress and diabetic complications.Circ Res. 2010; 107: 1058-1070
- Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes.Acta Diabetol. 2013; 50: 437-442
- Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?.Diabetes Metab. 2008; 34: 612-616
- Glycaemic variability is associated with coronary artery calcium in men with type 1 diabetes: the coronary artery calcification in type 1 diabetes study.Diabet Med. 2010; 27: 1436-1442
- Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients.Cardiovasc Diabetol. 2013; 12: 15
- Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction.Diabetes Care. 2013; 36: 1026-1032
- Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes.Diabetes Res Clin Pract. 2014; 105: 273-284
- Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose.J Clin Endocrinol Metab. 2000; 85: 4287-4292
- Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes.Diabetologia. 2007; 50: 2553-2561
- A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: the Diabetes Outcomes in Veterans Study (DOVES).Arch Intern Med. 2004; 164: 1445-1450
- The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes.Diabetes Technol Ther. 2011; 13: 813-818
- ADVANCE collaborative group. Severe hypoglycemia and risks of vascular events and death.N Engl J Med. 2010; 363: 1410-1418
- Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.Eur Heart J. 2013; 34: 3137-3144
- Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.Diabetes. 2014; 63: 1738-1747
- Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias.Diabetes Care. 2014; 37: 516-520
- Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept.Diabetes Metab Res Rev. 2009; 25: 393-402
- Glucose variability: an emerging target for the treatment of diabetes mellitus.Diabetes Res Clin Pract. 2013; 102: 86-95
- Glucose variability.Diabetes. 2013; 62: 1398-1404
- Glucose variability: where it is important and how to measure it.Diabetes. 2013; 62: 1405-1408
- Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes.Diabetes Care. 2015; 38: 140-149
- Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.Clin Ther. 2011; 33: 1932-1942
- Mean amplitude of glycemic excursions, a measure of diabetic instability.Diabetes. 1970; 19: 644-655
- The MiniMed Continuous Glucose Monitoring System (CGMS).J Pediatr Endocrinol Metab. 1999; 12: 751-758
- Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals.Diabetes Care. 2010; 33: 1297-1299
- Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia?.Diabetes Care. 2002; 25: 889-893
- Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia.Diabetes Technol Ther. 2005; 7: 876-884
- Value of continuous glucose monitoring for minimizing severe hypoglycemia during tight glycemic control.Pediatr Crit Care Med. 2011; 12: 643-648
- Real-time continuous glucose monitoring reduces the duration of hypoglycemia episodes: a randomized trial in very low birth weight neonates.PLoS One. 2015; 10: e0116255
- Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985; 28: 412-419
- Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data.Diabetes Technol Ther. 2012; 14: 1008-1012
- Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.Diabetologia. 2002; 45: 937-948
- Hypoglycemia in diabetes.Diabetes Care. 2003; 26: 1902-1912
- Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe?.J Diabetes Investig. 2014; 5: 475-477
- Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 2008; 358: 2545-2559
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 2008; 358: 2560-2572
- Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med. 2009; 360: 129-139
- Addressing self-monitoring of blood glucose: advocating paired glycemic testing for people with type 2 diabetes.J Diabetes Investig. 2012; 3: 337-338
Published online: January 13, 2016
Accepted: December 27, 2015
Received in revised form: November 27, 2015
Received: September 28, 2015
© 2016 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.